<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161536</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MCC-SA-0214</org_study_id>
    <nct_id>NCT02161536</nct_id>
  </id_info>
  <brief_title>Evaluation of the Performance of the Motus Cleansing System</brief_title>
  <acronym>MSC</acronym>
  <official_title>Evaluation of the Performance of the Motus Cleansing System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Motus GI Medical Technologies Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Motus GI Medical Technologies Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is evaluate the Motus GI Colon Cleansing system performance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects indicate for colonoscopy procedure undergo a limited bowel preparation including 20
      mg Bisacodyl (4*4 tables of 5 mg each) in split dose undergo standard colonoscopy with MCS.

      following the procedure 2 follow-up call were conducted at 48 hours and 14 days after to the
      procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Bowel cleansing level was evaluated by using the Boston Bowel Preparation Score (BBPS) at baseline and after the use of the Motus Cleansing System.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Count and Percentage of Subjects Had Adequate Bowel Preparation After the Use of Motus Cleansing Stystem</measure>
    <time_frame>Following the colonoscopic procedure- Up to 24 hours.</time_frame>
    <description>The number of subjects had adequate bowel preparation after the use of Motus Cleansing System (i.e., all colon segments have BBPS&gt;=2) .
Each colon segment was graded by using the Boston Bowel Preparation Score index before ( at baseline) and after the cleansing of the bowel by using the Motus Cleansing System.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Colonoscopy Procedure</condition>
  <arm_group>
    <arm_group_label>Motus CleanC System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colonoscopy with Motus CleanC Syetem - Device Rev 2.0 ,enrolled under protocol Rev 3.0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Motus Cleansing System Rev 2.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colonoscopy with MCS Rev 2.5,enrolled under protocol Rev 4.0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Motus Cleansing System Rev 3.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colonoscopy with MCS Rev 3.0,enrolled under protocol Rev 5.0</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Motus Cleansing System</intervention_name>
    <arm_group_label>Motus CleanC System</arm_group_label>
    <arm_group_label>Motus Cleansing System Rev 2.5</arm_group_label>
    <arm_group_label>Motus Cleansing System Rev 3.0</arm_group_label>
    <other_name>Motus CleanC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects in the age range of 18-75 years

          -  Subjects with BMI within the range of 18.5-35

          -  Subject is willing to sign informed consent form

        Exclusion Criteria:

          -  Active or severe IBD

          -  Subjects with severe diverticulitis \ diverticular disease (known or detected)

          -  Known or detected colonic stenosis

          -  Known or detected bowel obstruction

          -  History of prior colon surgery

          -  ASAâ‰¥IV (sever systemic disease)

          -  Sever Renal insufficiency

          -  Sever Liver insufficiency

          -  Contraindication for &quot;colonoscopy&quot; anesthesia \ sedation \ prep agent pregnancy

          -  Subjects with altered mental status/inability to provide informed consent

          -  Subject has a condition or is in a situation which in the investigators opinion may
             put the subject at significant risk, may confound the study results, or may interfere
             significantly
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravit Peled</last_name>
    <role>Study Director</role>
    <affiliation>Motus GI Technologies Ltd.</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2014</study_first_posted>
  <results_first_submitted>March 29, 2017</results_first_submitted>
  <results_first_submitted_qc>March 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 6, 2018</results_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in 3 phases:
Phase 1 - enrolled 6 subjects using Rev 2.0 of the device Phase 2 - enrolled 21 subjects using Rev 2.5 of the device Phase 3 - enrolled 20 subjects using Rev 3.0 of the device</recruitment_details>
      <pre_assignment_details>Patients had to follow a specific bowel preparation in order to mimic poor bowel preparation:
Arm 1: start clear liquid diet 24 hours prior to the procedure Arm 2: start clear liquid diet 24 hours prior to the procedure Arm 3: start clear liquid diet 18 hours prior to the procedure along with 4 tables of 5 mg Bisacodyl in split dose</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Motus CleanC Syetem Rev 2.0</title>
          <description>6 subjects used the second version of the device</description>
        </group>
        <group group_id="P2">
          <title>Motus Cleansing System Rev 2.5</title>
          <description>21 subjects enrolled under protocol Rev 4.0 , had a standard colonoscopy procedure with Motus Cleansing System Rev 2.5</description>
        </group>
        <group group_id="P3">
          <title>Motus Cleansing System Rev 3.0</title>
          <description>20 subjects enrolled under protocol Rev 5.0 , had a standard colonoscopy procedure with Motus Cleansing System Rev 3.0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Motus CleanC System Rev 2.0</title>
          <description>Motus CleanC System Rev 2.0</description>
        </group>
        <group group_id="B2">
          <title>Motus Cleansing System Rev 2.5</title>
          <description>Motus Cleansing System Rev 2.5</description>
        </group>
        <group group_id="B3">
          <title>Motus Cleansing System Rev 3.0</title>
          <description>Motus Cleansing System Rev 3.0</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>YEARS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="8.7"/>
                    <measurement group_id="B2" value="49.2" spread="11.6"/>
                    <measurement group_id="B3" value="54.7" spread="6.6"/>
                    <measurement group_id="B4" value="51.4" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Count and Percentage of Subjects Had Adequate Bowel Preparation After the Use of Motus Cleansing Stystem</title>
        <description>The number of subjects had adequate bowel preparation after the use of Motus Cleansing System (i.e., all colon segments have BBPS&gt;=2) .
Each colon segment was graded by using the Boston Bowel Preparation Score index before ( at baseline) and after the cleansing of the bowel by using the Motus Cleansing System.</description>
        <time_frame>Following the colonoscopic procedure- Up to 24 hours.</time_frame>
        <population>subjects had adequate bowel preparation after the use of Motus Cleansing System (i.e., all colon segments have BBPS&gt;=2)</population>
        <group_list>
          <group group_id="O1">
            <title>Motus CleanC System</title>
            <description>Colonoscopy with Motus CleanC Syetem - Device Rev 2.0 ,enrolled under protocol Rev 3.0
Motus Cleansing System</description>
          </group>
          <group group_id="O2">
            <title>Motus Cleansing System Rev 2.5</title>
            <description>Colonoscopy with MCS Rev 2.5,enrolled under protocol Rev 4.0
Motus Cleansing System</description>
          </group>
          <group group_id="O3">
            <title>Motus Cleansing System Rev 3.0</title>
            <description>Colonoscopy with MCS Rev 3.0,enrolled under protocol Rev 5.0
Motus Cleansing System</description>
          </group>
        </group_list>
        <measure>
          <title>The Count and Percentage of Subjects Had Adequate Bowel Preparation After the Use of Motus Cleansing Stystem</title>
          <description>The number of subjects had adequate bowel preparation after the use of Motus Cleansing System (i.e., all colon segments have BBPS&gt;=2) .
Each colon segment was graded by using the Boston Bowel Preparation Score index before ( at baseline) and after the cleansing of the bowel by using the Motus Cleansing System.</description>
          <population>subjects had adequate bowel preparation after the use of Motus Cleansing System (i.e., all colon segments have BBPS&gt;=2)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Motus CleanC Syetem Rev 2.0</title>
          <description>6 subjects used the second version of the device</description>
        </group>
        <group group_id="E2">
          <title>Motus Cleansing System Rev 2.5</title>
          <description>21 subjects enrolled under protocol Rev 4.0 , had a standard colonoscopy procedure with Motus Cleansing System Rev 2.5</description>
        </group>
        <group group_id="E3">
          <title>Motus Cleansing System Rev 3.0</title>
          <description>20 subjects enrolled under protocol Rev 5.0 , had a standard colonoscopy procedure with Motus Cleansing System Rev 3.0</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel perforation</sub_title>
                <description>The head design comprises flexible balcony-like in the tip which was beyond the scope's field of view, are suspected as the cause for the perforation.
The event was resolved with a scar as a residual effect.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <description>mild laceration resolved with no clinical sequelae within two days</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Erosion</sub_title>
                <description>mild erosion resolved with no clinical sequelae</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Submucosal Hematoma</sub_title>
                <description>mild Hematoma resolved with no clinical sequelae</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ravit Peled -Director of Clinical Trial</name_or_title>
      <organization>Motus GI Medical Technologies Ltd.</organization>
      <phone>+972 526145354</phone>
      <email>ravit@motusgi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

